Cannabinoids may worsen gastric dysmotility induced by chronic cisplatin in the rat

Neurogastroenterology and Motility

Volumn 25, Issue 5, 2013, Pages

  Abalo, R ^a   Cabezos, P A ^a   Vera, G ^a   Lopez Perez A E ^a   Martin M I ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Anorexia; Cannabinoids; Chemotherapy; Gastric emptying; Radiology

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CISPLATIN;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; DISEASE EXACERBATION; DISEASE SEVERITY; FOOD INTAKE; GASTRIC DYSMOTILITY; GASTROINTESTINAL TRACT FUNCTION; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH EMPTYING; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOXAZINES; CANNABINOIDS; CISPLATIN; DISEASE MODELS, ANIMAL; GASTROINTESTINAL MOTILITY; HYPERALGESIA; MALE; MORPHOLINES; NAPHTHALENES; RATS; RATS, WISTAR; WEIGHT LOSS;

EID: 84876726249     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12073     Document Type: Article

References (45)

1. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13: 27-46.
2. Trigg ME, Higa GM. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice. J Oncol Pharm Pract 2010; 16: 233-44.
3. Van Cutsem E, Arends J. The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 2005; 9(Suppl. 2): S51-63.
4. Vera G, Chiarlone A, Cabezos PA, Pascual D, Martín MI, Abalo R. WIN 55, 212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 2007; 81: 468-79.
5. Vera G, Chiarlone A, Martín MI, Abalo R. Altered feeding behaviour induced by long-term cisplatin in rats. Auton Neurosci 2006; 126-127: 81-92.
6. Takeda N, Hasegawa S, Morita M, Matsunaga T. Pica in rats is analogous to emesis: an animal model in emesis research. Pharmacol Biochem Behav 1993; 45: 817-21.
7. Mitchell D, Wells C, Hoch N, Lind K, Woods SC, Mitchell LK. Poison induced pica in rats. Physiol Behav 1976; 17: 691-7.
8. Bradner WT, Schurig JE. Toxicology screening in small animals. Cancer Treat Rev 1981; 8: 93-102.
9. Malik NM, Liu YL, Cole N, Sanger GJ, Andrews PL. Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats. Eur J Pharmacol 2007; 555: 164-73.
10. Cabezos PA, Vera G, Castillo M, Fernández-Pujol R, Martín MI, Abalo R. Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica. Auton Neurosci 2008; 141: 54-65.
11. Cabezos PA, Vera G, Martin-Fontelles MI, Fernandez-Pujol R, Abalo R. Cisplatin-induced gastrointestinal dysmotility is aggravated after chronic administration in the rat: comparison with pica. Neurogastroenterol Motil 2010; 22: 797-805.
12. Badary OA, Awad AS, Sherief MA, Hamada FM. In vitro and in vivo effects of ferulic acid on gastrointestinal motility: inhibition of cisplatin-induced delay in gastric emptying in rats. World J Gastroenterol 2006; 12: 5363-7.
13. Abalo R, Cabezos PA, López-Miranda V et al. Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55, 212-2 in the rat. Neurogastroenterol Motil 2009; 21: 1002-e80.
14. Abalo R, Cabezos PA, Vera G, Fernández-Pujol R, Martín MI. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55, 212-2 on gastrointestinal motility in the rat. Neurogastroenterol Motil 2010; 22: 694-e206.
15. Abalo R, Cabezos PA, Vera G, López-Miranda V, Herradón E, Martín-Fontelles MI. Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors. Neurogastroenterol Motil 2011; 23: 457-67. e177.
16. Abalo R, Vera G, López-Pérez AE, Martínez-Villaluenga M, Martín-Fontelles MI. The gastrointestinal pharmacology of cannabinoids: focus on motility. Pharmacology 2012; 90: 1-10.
17. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 2011; 22: 30-8.
18. Allen JH, de Moore GM, Heddle R et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004; 53: 1566-70.
19. Rudd JA, Andrews PLR. Mechanism of acute and delayed nausea and vomiting induced by anticancer therapies. In: Hesketh PJ, eds. Management of Nausea and Vomiting in Cancer and Cancer Treatment. Sudbury, MA: Jones and Bartlett, 2005: 27-31.
20. Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PL. Opportunities for the replacement of animals in the study of nausea and vomiting. Br J Pharmacol 2009; 157: 865-80.
21. Stern R, Koch KL, Andrews PLR. Nausea resulting from cancer and its treatment. In: Stern R, Koch KL, Andrews PLR, eds. Nausea, Mechanisms and Management. New York, USA: Oxford University Press, Inc., 2011: 315-29.
22. Authier N, Gillet JP, Fialip J et al. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 2003; 182: 12-20.
23. Compton DR, Rice KC, De Costa BR et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993; 65: 218-26.
24. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol 1992; 105: 980-4.
25. Bakitas MA. Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 2007; 56: 323-31.
26. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+)-WIN 55, 212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997; 221: 157-60.
27. Vera G, López-Miranda V, Herradón E, Martín MI, Abalo R. Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes. Pharmacol Biochem Behav 2012; 102: 335-43.
28. Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 2007; 152: 765-77.
29. Pascual D, Goicoechea C, Suardíaz M, Martín MI. A cannabinoid agonist, WIN 55, 212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 2005; 118: 23-34.
30. Costa B, Colleoni M, Conti S et al. Repeated treatment with the synthetic cannabinoid WIN 55, 212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 2004; 141: 4-8.
31. Burgos E, Gómez-Nicola D, Pascual D, Martín MI, Nieto-Sampedro M, Goicoechea C. Cannabinoid agonist WIN 55, 212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. Eur J Pharmacol 2012; 682: 62-72.
32. Osei-Hyiaman D. Endocannabinoid system in cancer cachexia. Curr Opin Clin Nutr Metab Care 2007; 10: 443-8.
33. Marco EM, Romero-Zerbo SY, Viveros MP, Bermudez-Silva FJ. The role of the endocannabinoid system in eating disorders: pharmacological implications. Behav Pharmacol 2012; 23: 526-36.
34. Vera G, Castillo M, Cabezos PA et al. Enteric neuropathy evoked by repeated cisplatin in the rat. Neurogastroenterol Motil 2011; 23: 370-8.
35. Vera Pasamontes G, Uranga JA, Martín-Fontelles MI, Abalo R. Histopathology of the severe effects induced by repeated cisplatin in rat digestive tissues. Neurogastroenterol Motil 2012; 24(Suppl. S2): 49.
36. Tramer MR, Carroll D, Campbell FA et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323: 16-21.
37. Gill EW, Paton WD, Pertwee RG. Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 1970; 228: 134-6.
38. Pertwee RG, Fernando SR, Nash JE, Coutts AA. Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol 1996; 118: 2199-205.
39. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001; 48: 859-67.
40. Abalo R, Vera G, Rivera AJ, Martín MI. Age-related changes in the gastrointestinal tract: a functional and immunohistochemical study in guinea-pig ileum. Life Sci 2007; 80: 2436-45.
41. Abalo R, Vera G, Rivera AJ, Moro-Rodríguez E, Martín-Fontelles MI. Postnatal maturation of the gastrointestinal tract: a functional and immunohistochemical study in the guinea-pig ileum at weaning. Neurosci Lett 2009; 467: 105-10.
42. Sangeetha P, Das UN, Koratkar R, Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Radic Biol Med 1990; 8: 15-9.
43. Stern R, Koch KL, Andrews PLR. The autonomic nervous system and nausea. In: Stern R, Koch KL, Andrews PLR, eds. Nausea, Mechanisms and Management. New York, USA: Oxford University Press, Inc., 2011: 77-114.
44. Vera Pasamontes G, Cabezos PA, Lopez AE, Martín-Fontelles MI, Abalo R. Granisetron prevents alterations of gastrointestinal motility in rats repeatedly treated with cisplatin: radiographic study. Neurogastroenterol Motil 2012; 24(Suppl. S2): 60-1.
45. Sanger GJ. Endocannabinoids and the gastrointestinal tract: what are the key questions?Br J Pharmacol 2007; 152: 663-70.